Immunotherapy drug shows promise for Hard-to-Treat colorectal cancer
NCT ID NCT05131919
First seen Jan 09, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tests the drug pembrolizumab in 25 adults with a specific type of advanced colorectal cancer (dMMR) that cannot be surgically removed. The goal is to see if the drug can shrink tumors enough to allow surgery or avoid it altogether. Researchers will also look for markers to identify patients who may not need surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Netherlands Cancer Institute
Amsterdam, 1066 CX, Netherlands
Conditions
Explore the condition pages connected to this study.